Treatment with pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer: a multicenter real-world study
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359221085232
Abstract: Background: Tyrosine kinase inhibitors (TKIs) are effective for treating human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. However, therapies subsequent to TKI progression remain controversial, and effective treatments for TKI resistance are urgently… read more here.
Keywords: positive metastatic; pyrotinib based; based therapy; breast cancer ... See more keywords
The efficacy of pyrotinib-based therapy in lapatinib-resistant metastatic HER2-positive breast cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Annals of palliative medicine"
DOI: 10.21037/apm-21-3965
Abstract: BACKGROUND Human epidermal growth factor receptor 2 (HER2)-positive breast cancer tends to metastasize and is associated with poor prognosis. Anti-HER2 treatment combined with chemotherapy or endocrine therapy is often used for HER2-positive metastatic breast cancer… read more here.
Keywords: lapatinib resistant; pyrotinib based; breast cancer; her2 ... See more keywords